Literature DB >> 23922048

The response of the autonomic nervous system to the cholinesterase inhibitor, donepezil.

Hiroyuki Umegaki1, Oyun Khookhor.   

Abstract

OBJECTIVE: Donepezil, a cholinesterase inhibitor (ChEI) that is widely used to treat Alzheimer's disease, is thought to act by increasing extracellular acethylcholine (ACh) in the central nervous system. The effects of the administration of ChEIs on the autonomic nervous system, however, are complex and controversial.
METHODS: In this study we observed the effects of donepezil at a dose of 3 mg/kg intraperitoneally (i.p.) on the autonomic nervous system for two weeks using heart rate variability (HRV). In HRV, the high frequency (HF) band is influenced by cardiac parasympathetic tone, and the low frequency (LF) band is influenced by both sympathetic and parasympathetic activity. The ratio of LF and HF (LF/HF) is used for the assessment of the sympathetic nervous system.
RESULTS: In the current study the LF/HF was found to be significantly increased by day 1, but the magnitude of the response gradually decreased. The absolute power of HF increased after an i.p of donepezil of 3 mg daily in groups treated for 1 week and for 2 weeks compared to the single-dose groups.
CONCLUSION: Our results suggested that ChEI administration induced sympathetic nervous activation acutely, but chronic administration induced parasympathetic activation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23922048

Source DB:  PubMed          Journal:  Neuro Endocrinol Lett        ISSN: 0172-780X            Impact factor:   0.765


  6 in total

1.  Donepezil induces ventricular arrhythmias by delayed repolarisation.

Authors:  Jason Kho; Adam Ioannou; Amit K J Mandal; Constantinos G Missouris
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-24       Impact factor: 3.000

2.  Analysis of electropharmacological and proarrhythmic effects of donepezil using the halothane-anesthetized intact dogs and the conscious chronic atrioventricular block ones.

Authors:  Mihoko Hagiwara-Nagasawa; Ryuichi Kambayashi; Ai Goto; Yoshio Nunoi; Hiroko Izumi-Nakaseko; Koki Chiba; Takeshi Wada; Yoshinori Takei; Akio Matsumoto; Atsushi Sugiyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-10-16       Impact factor: 3.000

3.  Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non-hypertensive Alzheimer's patients.

Authors:  Faez Saleh Al-Hamed; Stamatis Kouniaris; Iskandar Tamimi; Marie Lordkipanidzé; Sreenath Arekunnath Madathil; Abbas Kezouh; Igor Karp; Belinda Nicolau; Faleh Tamimi
Journal:  Alzheimers Dement (N Y)       Date:  2021-08-20

4.  Long-Term Blood Pressure Variability Across the Clinical and Biomarker Spectrum of Alzheimer's Disease.

Authors:  Isabel J Sible; Daniel A Nation
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Altered Behavioral and Autonomic Pain Responses in Alzheimer's Disease Are Associated with Dysfunctional Affective, Self-Reflective and Salience Network Resting-State Connectivity.

Authors:  Paul A Beach; Jonathan T Huck; David C Zhu; Andrea C Bozoki
Journal:  Front Aging Neurosci       Date:  2017-09-14       Impact factor: 5.750

6.  Antemortem Visit-To-Visit Blood Pressure Variability Predicts Cerebrovascular Lesion Burden in Autopsy-Confirmed Alzheimer's Disease.

Authors:  Isabel J Sible; Katherine J Bangen; Anna E Blanken; Jean K Ho; Daniel A Nation
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.